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Antigen processing: HLA-DO — a hitchhiking inhibitor of HLA-DM
Peter E. Jensen
Recent studies have revealed that the conserved major
histocompatibility complex class II molecule, HLA-DO,
inhibits the class II antigen-processing pathway. 
HLA-DO, expressed in only a subset of antigen-
presenting cells, binds HLA-DM and blocks HLA-DM-
catalyzed peptide loading of class II molecules.
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Major histocompatibility complex (MHC) class II mole-
cules are key players in the adaptive immune response.
Their role is to sample peptides derived from the break-
down of proteins present in the endosomal compartments
of specialized antigen-presenting cells. After stably
binding peptide, these molecules move to the cell surface
to display their cargo for recognition by CD4+ helper T
cells. In this way, helper T cells constantly monitor the
contents of the endosomal compartments of antigen-pre-
senting cells. The endosomes and lysosomes are good
compartments to sample because they are enriched for
proteins that are selectively internalized by antigen-pre-
senting cells, which have evolved mechanisms for uptake
of components of microbial pathogens. For example, B
cells efficiently internalize antigens through clonally dis-
tributed membrane immunoglobulin receptors. The pep-
tides displayed by the MHC class II molecules on the
surface of B cells are enriched in those derived from these
selectively internalized proteins. This process provides a
mechanism for T cells to recognize and interact with B
cells that have the same antigen specificity.
This endosomal sampling mechanism presents a particular
problem because MHC molecules are inherently unstable
without bound peptide antigen. Once bound, the peptide
is situated deep in the peptide-binding site of the MHC
molecule, providing interactions essential for stabilizing
the correctly folded molecule. As membrane proteins, the
α and β subunits of MHC class II molecules initially
assemble in the endoplasmic reticulum and the hetero-
dimers must be stabilized before they can be exported
from this compartment and routed through the Golgi
complex to endosomal vesicles. A specialized membrane-
bound chaperone protein, the MHC class II-associated
invariant chain, stabilizes the αβ heterodimer. A segment
of the invariant chain appears to interact directly with the
peptide-binding site, thereby providing a surrogate
peptide to stabilize the assembly of the class II molecule.
After transport to endosomal compartments, the invariant
chain is rapidly degraded by proteases leaving only a short
fragment that is protected from proteases because it is
buried in the peptide-binding site. This fragment, termed
CLIP (class II-associated invariant chain peptide), must
be released, however, so that the class II molecules can
bind locally generated peptides and sample the endoso-
mal environment.
Remarkably, a wayward member of the MHC class II
family is involved in the displacement of CLIP from the
peptide-binding site. HLA-DM is a membrane-bound
heterodimer encoded by adjacent genes in the class II
region of the MHC gene cluster. The amino acid
sequences of the α and β subunits share approximately
only 25% similarity to the corresponding subunits of other
MHC class II proteins such as HLA-DR, but the domain
organization and general conformation of HLA-DM are
likely to be very similar to other MHC class II proteins. In
contrast with HLA-DR, HLA-DP, and HLA-DQ, HLA-
DM has relatively little polymorphism and does not bind
peptide antigens. Additional cysteine residues in the
membrane-distal domains might create disulfide bonds
that preclude the formation of a functional peptide-
binding site. 
HLA-DM is selectively targeted to endosomal compart-
ments where it directly catalyzes the release of CLIP from
class II MHC molecules, freeing the peptide-binding sites
to bind ‘authentic’ peptide antigens [1–4]. HLA-DM
interacts directly with MHC class II proteins, apparently
inducing or stabilizing a transient conformational state that
favors peptide dissociation [5]. HLA-DM can enhance the
release of any peptide but the HLA-DM-catalyzed disso-
ciation rate is directly proportional to the intrinsic rate of
peptide dissociation that is observed in the absence of
HLA-DM. Thus, if peptides are released very slowly from
class II molecules, they dissociate slowly even in the pres-
ence of HLA-DM. CLIP is rapidly released in the pres-
ence of HLA-DM because its intrinsic rate of dissociation
is relatively rapid, but not fast enough to be released
without the help of HLA-DM under physiological condi-
tions. The broad specificity of HLA-DM suggests that it
might be able to catalyze multiple rounds of peptide
exchange in which subpopulations of lower affinity pep-
tides are successively replaced by higher affinity peptides
before the final population of MHC class II–peptide com-
plexes are transported out of HLA-DM-containing com-
partments on their way to the cell surface. It is striking
that the basic structure of the MHC class II molecule,
which has evolved to bind and display peptide antigens,
has been usurped in HLA-DM to play a very different role
— the catalysis of peptide exchange in sister molecules.
Several recent studies have indicated that the capacity of
class II histocompatibility molecules to have unexpected
functions does not end with HLA-DM [6–8]. The func-
tion of HLA-DO, a heterodimeric protein encoded by the
HLA-DNA and HLA-DOB genes in the class II region of
the MHC gene complex, has long remained elusive. This
protein has a high degree of similarity to HLA-DR, HLA-
DP, and HLA-DQ but differs from these proteins in its
limited polymorphism. Early studies by Lars Karlsson and
colleagues [9,10] demonstrated that the murine homo-
logue of HLA-DO (H-2O) is expressed at low levels as a
heterodimer with limited tissue distribution, predomi-
nantly in B cells and thymic medullary epithelium. The
high degree of evolutionary conservation of HLA-DO
suggests it has an important function. This molecule is
not expressed at the cell surface and therefore it is
unlikely to serve as a specialized antigen-presentation
molecule. An important advance was made in 1996 by
Karlsson and colleagues [6], who demonstrated that HLA-
DO forms stable complexes with HLA-DM in B cells.
Surprisingly, association with HLA-DM was found to be
required for HLA-DO to exit the endoplasmic reticulum.
HLA-DO then ‘hitches a ride’ with HLA-DM to lyso-
some-related MHC class II compartments (MIICs) where
most peptide loading occurs. It appears that HLA-DO
remains largely or completely associated with HLA-DM
in these compartments. The stoichiometry of this associa-
tion is unclear and might vary depending on cell type or
state of activation. These results suggest that HLA-DO
might have some role in regulating HLA-DM-catalyzed
peptide loading in B cells.
Two recent studies have demonstrated that HLA-DO
inhibits HLA-DM activity [7,8]. In both studies, HLA-
DM-catalyzed peptide loading was shown to be inhibited
in cells expressing exogenous HLA-DO. Overexpression
of HLA-DO results in a phenotype similar to HLA-DM-
deficient cells in that most of the MHC class II molecules
expressed at the cell surface contain CLIPs rather than
the heterogeneous population of peptides that is observed
in normal cells. HLA-DO expression does not affect the
steady-state expression level or the intracellular distribu-
tion of HLA-DM and the HLA-DO protein does not
detectably associate with other class II molecules. Studies
by van Ham et al. [8] revealed that, compared with lysates
from cells expressing HLA-DM alone, detergent lysates of
cells expressing both HLA-DM and HLA-DO were
markedly deficient in catalyzing peptide release or
peptide exchange in experiments with purified HLA-DR
molecules. Importantly, similar results were observed in
studies of lysates from purified MIIC vesicles. Thus,
HLA-DO continues to inhibit HLA-DM function after
delivery to endosomal compartments. The conclusion that
HLA-DO directly inhibits HLA-DM activity is supported
by the experiments of Denzin et al. [7], who showed that
purified HLA-DM–HLA-DO complexes have little or no
catalytic activity in peptide-exchange reactions.
Why is an inhibitor of antigen processing expressed in B
cells? Given the unique role of the B cell in presenting
antigens that have been internalized through surface
immunoglobulin, it is appealing to consider the possibil-
ity that triggering the B-cell receptor might induce signals
that release HLA-DO from HLA-DM, through selective
proteolysis or some other mechanism [7,8] (Figure 1).
Transcription of the HLA-DO and HLA-DM genes is
differentially regulated: HLA-DO is not induced by the
class II transactivator, CIITA, which induces the expres-
sion of HLA-DM, other class II molecules and the invari-
ant chain. It is possible that the ratio of HLA-DM to
HLA-DO is increased in B cells activated under certain
conditions in which the upregulation of antigen-process-
ing activity is important. At present, however, little is
known about the effect of different activation signals on
net HLA-DM activity in B cells, and there is no direct
evidence that cross-linking the B-cell receptor modulates
the inhibitor activity of HLA-DO.
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Figure 1
HLA-DO inhibitory activity might be regulated in endosomal
compartments. Functional HLA-DM could be dissociated from 
HLA-DM–HLA-DO complexes by proteolytic cleavage of HLA-DO or
other mechanisms. HLA-DM would then be able to catalyze the
replacement of CLIP with other peptides on HLA-DR molecules. The
release of HLA-DO from HLA-DM would provide a mechanism to
upregulate HLA-DM activity rapidly or to limit peptide loading to a
specific subset of endosomal compartments.
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Recent studies from Lars Karlsson’s group support the
hypothesis that HLA-DO plays a role in regulating the
specificity of antigen presentation by B cells. This group
has created mice lacking the expression of functional H-
2O by targeted disruption of the H-2Oa gene. Analysis of
B cells from these animals and B cells from wild-type mice
suggests that HLA-DO selectively inhibits presentation of
antigens that are internalized non-specifically by fluid-
phase pinocytosis, favoring presentation of antigens inter-
nalized through the membrane immunoglobulin receptor
(L. Karlsson, personal communication). Their studies with
recombinant HLA-DM and HLA-DO proteins provide a
potential mechanism. As reported by Denzin et al. [7] and
van Ham et al. [8], HLA-DM–HLA-DO complexes were
observed to have no catalytic activity under most condi-
tions. HLA-DM activity was observed, however, under
pH conditions similar to those of the most acidic compart-
ments in the endosomal pathway (L. Karlsson, personal
communication). In the presence of HLA-DO, peptide
loading might be limited to these acidic compartments,
which are probably enriched for antigens internalized
through the B-cell receptor.
The observation that HLA-DO is selectively expressed
in B cells and thymic medullary epithelial cells raises the
interesting possibility that this molecule might play a
role in tolerance induction. It has been demonstrated
that resting B cells can induce peripheral T-cell toler-
ance [11,12]. By partially downregulating HLA-DM
activity, HLA-DO might allow CLIP to be replaced by a
population of peptide antigens while inhibiting subse-
quent rounds of peptide exchange that would skew the
repertoire of presented antigens by favoring only very
stable MHC class II–peptide complexes. In this way,
HLA-DO may broaden or alter the repertoire of peptides
presented to CD4+ T cells (Figure 2). Katz et al. [13]
have clearly demonstrated that HLA-DM overexpression
can reduce the expression of a subset of MHC class
II–peptide complexes. Most peptides presented by class
II molecules are derived from the breakdown of self-
expressed proteins that are represented in endosomal
compartments. HLA-DO might serve to expand self-tol-
erance by altering the repertoire of the ‘self’ peptides
that are presented in a subset of antigen-presenting cells
capable of inducing tolerance.
Despite these recent advances, the physiological role(s) of
HLA-DO remain uncertain. Although HLA-DM activity
in B cells could be controlled at the level of transcription,
certain advantages might result from a mechanism using
an inhibitor protein to regulate HLA-DM function. In
contrast with CIITA, HLA-DO selectively modulates
HLA-DM activity without affecting the expression of the
invariant chain or other class II molecules such as HLA-
DR. Therefore, HLA-DO may provide a mechanism to
partially downregulate HLA-DM activity without affect-
ing the level of expression of cell-surface class II mole-
cules. This mode of action would clearly be advantageous
if HLA-DO-expressing cells have a role in broadening
CD4+ T-cell tolerance, as discussed above. Protein-medi-
ated regulation would also provide the potential for very
rapid enhancement of HLA-DM activity if there is a
mechanism for inducing the release of HLA-DO. It
should also be noted that human dendritic cells cultured
with GM-CSF have been reported to express HLA-DO
[14], raising the possibility that HLA-DO may regulate
HLA-DM function in this important class of antigen-pre-
senting cell. Clearly, more work must be carried out
before we understand fully the physiological role of this
hitchhiking inhibitor.
Figure 2
HLA-DO might modify the repertoire of
peptides presented by class II molecules on B
cells and thymic epithelial cells. After
catalyzing an initial round of peptide exchange
in which CLIP is replaced by a population of
peptides with a wide range of affinities, 
HLA-DM may catalyze further rounds of
peptide exchange. In this way, HLA-DM may
narrow the repertoire of presented peptides
favoring those with the highest affinity for
class II molecules. By partially inhibiting this
editing activity, HLA-DO could broaden the
population of peptides presented to CD4+
T cells.
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